Xu Weiwei, Ge Yan, Liu Zhihong, Gong Rujun
From the National Clinical Research Center of Kidney Disease, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China and the Division of Kidney Disease and Hypertension, Department of Medicine, Rhode Island Hospital, Brown University School of Medicine, Providence, Rhode Island 02903.
the Division of Kidney Disease and Hypertension, Department of Medicine, Rhode Island Hospital, Brown University School of Medicine, Providence, Rhode Island 02903.
J Biol Chem. 2015 Jan 16;290(3):1348-63. doi: 10.1074/jbc.M114.593830. Epub 2014 Dec 2.
Reminiscent of neural repair, following podocyte depletion, remnant-surviving podocytes exhibit a considerable adaptive capacity to expand and cover the denuded renal glomerular basement membrane. Microtubules, one of the principal cytoskeletal components of podocyte major processes, play a crucial role in podocyte morphogenesis and podocyte process outgrowth, branching, and elongation. Here, we demonstrated that the microtubule-associated proteins Tau and collapsin response mediator protein (CRMP) 2, key regulators of microtubule dynamics, were abundantly expressed by glomerular podocytes in vivo and in vitro, interacted with glycogen synthase kinase (GSK)3β, and served as its putative substrates. GSK3β overactivity induced by adriamycin injury or by a constitutively active mutant of GSK3β augmented phosphorylation of Tau and CRMP2, concomitant with microtubule depolymerization, cell body shrinkage, and shortening of podocyte processes. Conversely, inhibition of GSK3β by a dominant negative mutant or by lithium, a Food and Drug Administration-approved neuroprotective mood stabilizer, diminished Tau and CRMP2 phosphorylation, resulting in microtubule polymerization, podocyte expansion, and lengthening of podocyte processes. In a mouse model of adriamycin-induced podocyte depletion and nephropathy, delayed administration of a single low dose of lithium attenuated proteinuria and ameliorated progressive glomerulosclerosis despite no correction of podocytopenia. Mechanistically, lithium therapy obliterated GSK3β overactivity, mitigated phosphorylation of Tau and CRMP2, and enhanced microtubule polymerization and stabilization in glomeruli in adriamycin-injured kidneys, associated with elongation of podocyte major processes. Collectively, our findings suggest that the GSK3β-dictated podocyte microtubule dynamics might serve as a novel therapeutic target to reinforce the compensatory glomerular adaptation to podocyte loss.
与神经修复类似,在足细胞耗竭后,残留存活的足细胞表现出相当大的适应性能力来扩张并覆盖裸露的肾小球基底膜。微管是足细胞主要突起的主要细胞骨架成分之一,在足细胞形态发生以及足细胞突起的生长、分支和延长中起关键作用。在此,我们证明了微管相关蛋白Tau和塌陷反应介导蛋白(CRMP)2,作为微管动力学的关键调节因子,在体内和体外均由肾小球足细胞大量表达,与糖原合酶激酶(GSK)3β相互作用,并作为其假定底物。阿霉素损伤或GSK3β的组成型活性突变体诱导的GSK3β过度活性增强了Tau和CRMP2的磷酸化,同时伴有微管解聚、细胞体收缩和足细胞突起缩短。相反,显性负性突变体或锂(一种美国食品药品监督管理局批准的神经保护性情绪稳定剂)对GSK3β的抑制作用减少了Tau和CRMP2的磷酸化,导致微管聚合、足细胞扩张和足细胞突起延长。在阿霉素诱导的足细胞耗竭和肾病的小鼠模型中,延迟单次给予低剂量锂可减轻蛋白尿并改善进行性肾小球硬化,尽管足细胞减少未得到纠正。从机制上讲,锂治疗消除了GSK3β的过度活性,减轻了Tau和CRMP2的磷酸化,并增强了阿霉素损伤肾脏中肾小球的微管聚合和稳定性,这与足细胞主要突起的延长有关。总体而言,我们的研究结果表明,GSK3β主导的足细胞微管动力学可能作为一个新的治疗靶点,以加强肾小球对足细胞丢失的代偿性适应。